Sysmex Corporation

Sysmex and Hitachi High-Tech Agree to Collaborate on Development of New Genetic Testing Systems

Retrieved on: 
Thursday, February 8, 2024

TOKYO, Feb 8, 2024 - (JCN Newswire) - Sysmex Corporation and Hitachi High-Tech Corporation announce that both companies have agreed to collaborate in the development of genetic testing systems based on capillary electrophoresis sequencers (CE sequencers)(1).

Key Points: 
  • TOKYO, Feb 8, 2024 - (JCN Newswire) - Sysmex Corporation and Hitachi High-Tech Corporation announce that both companies have agreed to collaborate in the development of genetic testing systems based on capillary electrophoresis sequencers (CE sequencers)(1).
  • To achieve widespread clinical realization, Sysmex and Hitachi High-Tech will develop more efficient genetic testing systems at a lower cost, aiming at expanding optimal genetic testing for individual diseases.
  • In recent years, there has been active development of assay reagents using next generation sequencer (NGS)(2) in the genetic testing field.
  • Having achieved the milestones in the FS agreement, Sysmex and Hitachi High-Tech have agreed, as the next step, to collaborate on the development of genetic testing systems with a view to their widespread adoption in the clinical setting.

EQS-News: USU Secures Sysmex as First Japanese Customer for Knowledge Management

Retrieved on: 
Wednesday, January 17, 2024

Sysmex Corporation, headquartered in Kobe, Japan, will use USU Knowledge Management as a corporate-wide knowledge source for all technical queries.

Key Points: 
  • Sysmex Corporation, headquartered in Kobe, Japan, will use USU Knowledge Management as a corporate-wide knowledge source for all technical queries.
  • The specialist in laboratory analysis devices and in-vitro diagnostics, operating in more than 190 countries, plans to deploy the active USU knowledge database worldwide as a 'single source of truth' for all colleagues in customer service area in Sysmex and business partners.
  • The subsidiary Sysmex Europe has already been using USU Knowledge Management successfully for years.
  • USU Knowledge Management is scheduled to go live worldwide by mid-2024.

Fujirebio and Sysmex Sign Agreement for the Supply of Reagent Raw Materials in the Field of Immunoassay

Retrieved on: 
Thursday, December 14, 2023

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have signed an agreement for the mutual supply of reagent raw materials owned by both companies (“the Agreement”).

Key Points: 
  • Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have signed an agreement for the mutual supply of reagent raw materials owned by both companies (“the Agreement”).
  • The Agreement is based on a basic agreement on business collaboration in the field of immunoassay*1 which the two companies signed in October 2023.
  • In October 2023, Fujirebio and Sysmex entered into a basic agreement on business collaboration in the field of immunoassay, in a bid to promote cooperation to accelerate their global expansion, and to contribute to the development and advancement of immunoassay.
  • Under the terms of the Agreement, Fujirebio and Sysmex will mutually supply a wide range of reagent materials owned by each company, mainly antigens and antibodies, which are the main raw materials of immunoassay reagents.

Fujirebio and Sysmex Expand CDMO Partnership into the Field of Neurodegenerative Diseases under Their Immunoassay Collaboration

Retrieved on: 
Thursday, November 30, 2023

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have entered into an agreement to expand their Contract Development and Manufacturing Organization (CDMO) partnership for Sysmex's Automated Immunoassay System HISCL™-Series to include the field of neurodegenerative diseases, following the discussion based on the Basic Agreement on Business Collaboration in the field of immunoassay signed in October 2023*.

Key Points: 
  • Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have entered into an agreement to expand their Contract Development and Manufacturing Organization (CDMO) partnership for Sysmex's Automated Immunoassay System HISCL™-Series to include the field of neurodegenerative diseases, following the discussion based on the Basic Agreement on Business Collaboration in the field of immunoassay signed in October 2023*.
  • Under the terms of the new agreement, in the field of neurodegenerative diseases including Alzheimer's Disease, Fujirebio will develop reagents for Sysmex's HISCL™-Series for cerebral spinal fluid (CSF)-based testing as well as blood-based testing.
  • This will accelerate the expansion of Sysmex’s testing parameters in the diseases field, further propelling the expansion of its global footprint in immunoassay.
  • Fujirebio and Sysmex will further collaborate to develop and launch the tests as early as possible.

VCCT Inc., Leading the Field of Retinal Regeneration through iPS Cells, Raises 600 million Japanese yen (approximately $4 million USD) through Third-Party Allotment.

Retrieved on: 
Wednesday, November 15, 2023

VCCT Inc.(President: Masayo Takahashi) is pleased to announce the completion of a private equity allotment of approximately 600 million yen ($4 million USD).

Key Points: 
  • VCCT Inc.(President: Masayo Takahashi) is pleased to announce the completion of a private equity allotment of approximately 600 million yen ($4 million USD).
  • With the completion of this fundraising round, the total amount of funds raised by VCCT now amounts to 1.7 billion yen ($11.3 million USD).
  • VCCT is dedicated to the development and application of cutting-edge cell therapy treatments focusing on retinal diseases.
  • As a front runner in regenerative medicine research, VCCT has accumulated a wealth of clinical expertise in this field.

Fujirebio and Sysmex Enter into Basic Agreement on Business Collaboration in the Field of Immunoassay

Retrieved on: 
Tuesday, October 10, 2023

Sysmex has built up a robust technological foundation as well as a global network in the in vitro diagnostics field through developing its business in this field for more than 50 years.

Key Points: 
  • Sysmex has built up a robust technological foundation as well as a global network in the in vitro diagnostics field through developing its business in this field for more than 50 years.
  • In order to further reinforce its diagnostics business, the company aims to speed up expansion of its immunochemistry business in the global markets including U.S. and Europe.
  • Fujirebio has a wide range of reagent raw materials and product portfolios through its long-standing business in the immunoassay.
  • Fujirebio and Sysmex aim to deliver high value testing to global customers as early as possible driven by strengthened partnership in immunoassay.

Flow Cytometry Market worth $7.0 billion | MarketsandMarkets

Retrieved on: 
Wednesday, August 9, 2023

In June 2023, BD launched The BD FACSDuet Premium Sample Preparation System to automate sample preparation in clinical flow cytometry diagnostics.

Key Points: 
  • In June 2023, BD launched The BD FACSDuet Premium Sample Preparation System to automate sample preparation in clinical flow cytometry diagnostics.
  • In May 2023, Sysmex launched Clinical Flow Cytometry System Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products in Japan.
  • Personalized Medicine: Flow cytometry contributes to personalized medicine by enabling tailored treatments based on individual patient profiles and disease characteristics.
  • These pointers highlight the multifaceted advantages of flow cytometry, making it an indispensable tool in scientific research, clinical diagnostics, and healthcare innovation.

Flow Cytometry Market worth $7.0 billion | MarketsandMarkets

Retrieved on: 
Wednesday, August 9, 2023

In June 2023, BD launched The BD FACSDuet Premium Sample Preparation System to automate sample preparation in clinical flow cytometry diagnostics.

Key Points: 
  • In June 2023, BD launched The BD FACSDuet Premium Sample Preparation System to automate sample preparation in clinical flow cytometry diagnostics.
  • In May 2023, Sysmex launched Clinical Flow Cytometry System Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products in Japan.
  • Personalized Medicine: Flow cytometry contributes to personalized medicine by enabling tailored treatments based on individual patient profiles and disease characteristics.
  • These pointers highlight the multifaceted advantages of flow cytometry, making it an indispensable tool in scientific research, clinical diagnostics, and healthcare innovation.

Roche expands long-term alliance with Sysmex

Retrieved on: 
Thursday, August 3, 2023

Roche has been collaborating with Sysmex for 25 years and through the renewed terms, Roche will continue to offer Sysmex' hematology products, complementing their total lab solutions portfolio.

Key Points: 
  • Roche has been collaborating with Sysmex for 25 years and through the renewed terms, Roche will continue to offer Sysmex' hematology products, complementing their total lab solutions portfolio.
  • "We are delighted to expand our 25-year partnership with Sysmex in the area of hematology and in exploring more sustainable diagnostics solutions.
  • Roche and Sysmex both have a long-standing history of delivering reliable and innovative solutions for patients and I am very happy to see this collaboration grow," said Matt Sause, CEO of Roche Diagnostics.
  • "We are pleased to announce the renewal of our partnership with Roche, reaffirming our commitment to long-term collaboration.

Roche expands long-term alliance with Sysmex

Retrieved on: 
Thursday, August 3, 2023

Roche has been collaborating with Sysmex for 25 years and through the renewed terms, Roche will continue to offer Sysmex' hematology products, complementing their total lab solutions portfolio.

Key Points: 
  • Roche has been collaborating with Sysmex for 25 years and through the renewed terms, Roche will continue to offer Sysmex' hematology products, complementing their total lab solutions portfolio.
  • "We are delighted to expand our 25-year partnership with Sysmex in the area of hematology and in exploring more sustainable diagnostics solutions.
  • Roche and Sysmex both have a long-standing history of delivering reliable and innovative solutions for patients and I am very happy to see this collaboration grow," said Matt Sause, CEO of Roche Diagnostics.
  • "We are pleased to announce the renewal of our partnership with Roche, reaffirming our commitment to long-term collaboration.